Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model

Cancer Research

Volumn 66, Issue 8, 2006, Pages 4503-4511

  Ouyang, Nengtai ^a   Williams, Jennie L ^a   Tsioulias, George J ^b   Gao, Jianjun ^a   Iatropoulos, Michael J ^d   Kopelovich, Levy ^e   Kashfi, Khosrow ^c   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIS(2 OXOPROPYL)NITROSAMINE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; CYCLOOXYGENASE 2; DNA NUCLEOTIDYLEXOTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MOLECULAR MARKER; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER STAGING; CARCINOGENESIS; CARCINOMA; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVATION; FEMALE; HISTOPATHOLOGY; NICK END LABELING; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYRIAN HAMSTER; TUMOR CELL; TUMOR MODEL;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; ASPIRIN; CARCINOGENS; CELL GROWTH PROCESSES; CRICETINAE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; FEMALE; MESOCRICETUS; NF-KAPPA B; NITRIC OXIDE DONORS; NITROSAMINES; PANCREAS; PANCREATIC NEOPLASMS;

EID: 33646268630     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3118     Document Type: Article

References (41)

1. American Cancer Society. Cancer facts and figures 2005 Atlanta (Georgia): American Cancer Society; 2005.
2. Yip-Schneider MT, Sweeney CJ, Jung SH, Crowell PL, Marshall MS. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 2001;298:976-85.
3. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59:4356-62.
4. Takahashi M, Furukawa F, Toyoda K, et al. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1990;11:393-5.
5. Anderson KE, Johnson TW, Lazovich D, Folsom AR. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 2002;94:1168-71.
6. Coogan PF, Rosenberg L, Palmer JR, et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000;9:119-23.
7. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000;320:1642-6.
8. Menezes RJ, Huber KR, Mahoney MC, Moysich KB. Regular use of aspirin and pancreatic cancer risk. BMC Public Health 2002;2:18.
9. Schernhammer ES, Kang JH, Chan AT, et al. A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 2004;496:22-8.
10. Baron JA. What now for aspirin and cancer prevention? J Natl Cancer Inst 2004;96:4-5.
11. Rigas B, Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 2004;10:324-30.
12. Iconomou G, Kalofonos HP, Koutras A, Vagenakis AG, Rigas B. A pilot study of no-donating aspirin in patients with pancreatic cancer pain. J Support Oncol. In press 2006.
13. Nath N, Kashfi K, Chen J, Rigas B. Nitric oxide-donating aspirin inhibits β-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear β-catenin-TCF association. Proc Natl Acad Sci U S A 2003;100:12584-9.
14. Spiegel A, Hundley TR, Chen J, et al. NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells. Biochem Pharmacol 2005;70:993-1000.
15. Hundley TR, Rigas B. NO-donating aspirin inhibits colon cancer cell growth via MAP kinase activation. J Pharmacol Exp Ther 2006;316:25-34.
16. Gao J, Kashfi K, Liu X, Rigas B. NO-donating aspirin induces phase II enzymes in vitro and in vivo. Carcinogenesis. In press 2006.
17. Gao J, Liu X, Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc Natl Acad Sci U S A 2005;102:17207-12.
18. Kashfi K, Ryann Y, Qiao LL, et al. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells evidence of a tissue type-independent effect. J Pharmacol Exp Ther 2002;303:1273-82.
19. Birt DF, Pour PM, Nagel DL, Barnett T, Blackwood D, Duysen E. Dietary energy restriction does not inhibit pancreatic carcinogenesis by N-nitrosobis-2-(oxopropyl)amine in the Syrian hamster. Carcinogenesis 1997;18:2107-11.
20. Hall PA, Lemoine NR. Models of pancreatic cancer. Cancer Surv 1993;16:135-55.
21. Tsutsumi M, Kondoh S, Noguchi O, et al. K-ras gene mutation in early ductal lesions induced in a rapid production model for pancreatic carcinomas in Syrian hamsters. Jpn J Cancer Res 1993;84:1101-5.
22. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001;25:579-86.
23. Hershenson MB. p21Waf1/Cip1 and the prevention of oxidative stress. Am J Physiol Lung Cell Mol Physiol 2004;286:L502-5.
24. Algul H, Adler G, Schmid RM. NF-κB/Rel transcriptional pathway: implications in pancreatic cancer. Int J Gastrointest Cancer 2002;31:71-8.
25. Lin A, Karin M. NF-κB in cancer: a marked target. Semin Cancer Biol 2003;13:107-14.
26. Mann JR, DuBois RN. Cyclooxygenase-2 and gastrointestinal cancer. Cancer J 2004;10:145-52.
27. Furukawa F, Nishikawa A, Lee IS, et al. A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters. Int J Cancer 2003;104:269-73.
28. Lowy AM. Transgenic models of pancreatic cancer. Int J Gastrointest Cancer 2003;33:71-8.
29. Schuller HM, Jorquera R, Reichert A, Castonguay A. Transplacental induction of pancreas tumors in hamsters by ethanol and the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 1993;53:2498-501.
30. Royle JS, Ross JA, Ansell I, Bollina P, Tulloch DN, Habib FK. Nitric oxide donating nonsteroidal anti-inflammatory drugs induce apoptosis in human prostate cancer cell systems and human prostatic stroma via caspase-3. J Urol 2004;172:338-44.
31. Tesei A, Ulivi P, Fabbri F, et al. In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. J Transl Med 2005;3:7.
32. Williams JL, Borgo S, Hasan I, Castillo E, Traganos F, Rigas B. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res 2001;61:3285-9.
33. Wink DA, Mitchell JB. Nitric oxide and cancer: an introduction. Free Radic Biol Med 2003;34:951-4.
34. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005;65:3980-5.
35. Goldberg Y, Nassif II, Pittas A, et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996;12:S93-901.
36. Tseng WW, Deganutti A, Chen MN, Saxton RE, Liu CD. Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. J Gastrointest Surg 2002;6:838-43; discussion 844.
37. Wang CY, Guttridge DC, Mayo MW, Baldwin AS. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999;19:5923-9.
38. Fujioka S, Sclabas GM, Schmidt C, et al. Inhibition of constitutive NF-κB activity by IκB αM suppresses tumorigenesis. Oncogene 2003;22:1365-70.
39. Williams JL, Nath N, Chen J, et al. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and β-catenin/T-cell factor signaling, nuclear factor-κB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res 2003;63:7613-8.
40. Nobuoka A, Takayama T, Miyanishi K, et al. Glutathione-S-transferase Pl-1 protects aberrant crypt foci from apoptosis induced by deoxycholic acid. Gastroenterology 2004;127:428-43.
41. Nath N, Labaze G, Rigas B, Kashfi K. NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates β-catenin expression. Biochem Biophys Res Commun 2005;326:93-9.